However, the SH2 domain is highly conserved, making it difficult to find specific small molecule inhibitors for STAT3, leading to STAT3 classification as an “undruggable” protein.510 Recently, Kymera advanced its STAT3 degrader, KT-333 (214), into clinical trials for the treatment of hematologic malignancies and solid tumors (Table 4). The gene discussed is STAT3; the disease is hematologic disorder.